 |
|
|
|
|
|
 Title: |
US5484591:
Method for treating gram negative bacterial infections in humans
[ Derwent Title ]
|
| Country: |
US United States of America
|
| |
| Inventor: |
Young, Lowell S.; San Francisco, CA
|
| Assignee: |
The Regents of the University of California, Oakland, CA
other patents from UNIVERSITY OF CALIFORNIA, THE REGENTS OF (599425) (approx. 4,840)
News, Profiles, Stocks and More about this company
|
| Published / Filed: |
1996-01-16
/ 1994-07-01
|
| Application Number: |
US1994000277934
|
| IPC Code: |
Advanced:
C07K 16/12;
C12N 15/12;
G01N 33/569;
A61K 38/00;
Core:
more...
IPC-7:
A61K 39/40;
A61K 48/00;
C07K 16/12;
C12N 15/12;
|
| ECLA Code: |
C07K16/12A; C07K16/12A14; G01N33/569D2;
|
| U.S. Class: |
Current:
424/150.1;
424/164.1;
530/388.4;
Original:
424/150.1;
424/164.1;
530/388.4;
435/240.27;
|
| Field of Search: |
424/150.1,164.1
435/240.27
530/388.4
|
| Priority Number: |
| 1994-07-01 |
US1994000277934 |
| 1993-11-18 |
US1993000154142 |
| 1991-11-20 |
US1991000798031 |
| 1989-02-03 |
US1989000306712 |
| 1986-04-24 |
US1986000855878 |
| 1985-09-27 |
US1985000781242 |
|
| Abstract: |
The present invention provides novel hybridoma cell lines which produce monoclonal antibodies (MoAbs) that bind epitopes found on lipopolysaccharide most commonly associated with the endotoxin core of gram negative bacteria and exhibit broad cross-reactivity with gram negative bacteria of different genera and effectively neutralize endotoxin. At least one of the MoAbs disclosed (XMMEN-J5D) binds an epitope also found on gram positive bacteria. The hybridomas are produced by fusing an immortal cell, a cell having the ability to replicate indefinitely in myeloma cell culture, and an effector immune cell following immunization of the immune cell host with a preparation of a gram negative bacteria. While several individual hybridoma cell lines producing monoclonal antibodies to lipopolysaccharide are described, the present invention adds to the state of the art an entire family of hybridomas producing monoclonal antibodies to lipopolysaccharide-associated epitopes. The monoclonal antibodies produced by the hybridoma cell lines of the present invention are useful in the detection of bacterial infections, therapy and prophylaxis of bacterial endotoxemia and infection caused by gram negative bacteria.
|
| Attorney, Agent or Firm: |
Townsend and Townsend and Crew ;
|
| Primary / Asst. Examiners: |
Parr, Margaret; Loring, Susan A.
|
| Maintenance Status: |
E3 Expired Check current status
|
| INPADOC Legal Status: |
Show legal status actions
Family Legal Status Report
|
|
|
|
|
|
|
| Parent Case: |
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation U.S. application Ser. No. 08/154,142, filed Nov. 18, 1993, now abandoned, which was a continuation of U.S. application Ser. No. 07/798,031, filed Nov. 20, 1992, now abandoned, which was a continuation of U.S. application Ser. No. 07/306,712, filed Feb. 3, 1989, now abandoned, which was a continuation was a continuation of U.S. Ser. No. 06/855,878, filed Apr. 24, 1986 which issued as U.S. Pat. No. 4,918,163 and which was a continuation-in-part application of Ser. No. 06/781,242, filed Sep. 27, 1985 which issued as U.S. Pat. No. 4,777,136, the disclosures of which are hereby incorporated by reference.
|
| Designated Country: |
BE CH FR GB IT LI LU NL SE
|
| Family: |
Show 37 known family members
|
| Claim |
What is claimed is:
1. A method for therapeutically treating a human having a gram negative bacterial infection, comprising administering to the human a therapeutically effective amount of a monoclonal antibody produced by the hybridoma cell line ATCC Accession No. HB9081 (the "HB9081 antibody") or a monoclonal antibody of the IgM isotype which binds to an epitope recognized by the HB9081 antibody and further wherein the monoclonal antibody is administered in conjunction with antibiotic therapy for gram negative bacterial infections.
|
| Background / Summary: |
Show background / summary
|
| Drawing Descriptions: |
Show drawing descriptions
|
| Description: |
Show description
|
| Forward References: |
Show 2 U.S. patent(s) that reference this one
|
|
|
|
|
|
|
| Foreign References: |
|
| Other Abstract Info: |
CHEMABS 107(05)037948U
DERABS C1987-095524
DERABS C1992-227652
|
| Other References: |
Thorpe, R., TiBTECH, vol. 11, Feb. 1993, pp. 40-42.
Sloan, A., The Washington Post, Tuesday Jan. 19, 1993, D3.
Spalding, B. J., Bio/Technology, vol. 11:428-429, Apr. 1993.
(2 pages)
Cited by 18 patents
[ISI abstract]
Science, vol. 259:1243, Feb. 26, 1993.
Wenzel, The New England Journal of Medicine, vol. 326 (17): 1151-1152, Apr. 23, 1992.
(3 pages)
Cited by 4 patents
[ISI abstract]
Warren et al., The New England Journal of Medicine, vol. 326 (17): 1153-1157, Apr.23, 1992.
(5 pages)
Cited by 3 patents
[ISI abstract]
Ziegler, E. J., JID, 158 (2):286-290, AUG. 1988.
Baumgartner, et al., J. Exp. 889-896, Mar. 1, 1990.
(8 pages)
Cited by 8 patents
|
|
 Nominate this for the Gallery...
|
|
